Keywords: فاکتور 8; aFVII; activated FVII; AHA; acquired hemophilia A; anti-hFVIII; anti-human FVIII; aPCC; activated prothrombin complex concentrate; aPTT; activated partial thromboplastin time; AT; antithrombin; AUC; area under the curve; BPA; bypassing agent; BU; Bethesda
مقالات ISI فاکتور 8 (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: فاکتور 8; Hemophilia A; Factor VIII inhibitor; Inhibitor by passing activity; Activated prothrombin concentrate; Recombinant activated factor VII; Factor VIII; Novel agents; TFPI antagonists; ATIII antagonist; Concizumab; Emicizumab; Alpha 1 antitrypsin;
Keywords: فاکتور 8; formulation; pharmacokinetics; liposomes; proteins; pharmacodynamics; rhGAA; recombinant human acid α-glucosidase; PI; phosphatidylinositol; FVIII; factor VIII; GAA; acid α-glucosidase; 4-MUG; 4-methylumbelliferyl-α-d-glucopyranoside; PI-rhGAA; PI lipo
Keywords: فاکتور 8; VTE; venous thromboembolism; HSCT; hematopoietic stem cell transplant; LMWH; low molecular weight heparin; IMIDs; immunomodulatory drugs; AML; acute myeloid leukemia; IQR; interquartile range; TAT; thrombin antithrombin; FVII; factor VII; FVIII; factor VI
Keywords: فاکتور 8; Factor VIII; Hemophilia A; Blood coagulation; Recombinant proteins; Glycoprotein; Glycosylation;
Keywords: فاکتور 8; Bleeding; Hemarthrosis; Factor concentrate; Factor VIII; Factor IX; Inhibitors; Gene therapy; Bispecific antibody;
Keywords: فاکتور 8; Haemophilia; Factor VIII; Advancements in therapy;
Keywords: فاکتور 8; phospholipids; liposomes; apoptosis; immune response; proteins; biotechnology; HA; Hemophilia A; FVIII; factor VIII; GAA; acid alpha glucosidase; rhGAA; recombinant human GAA; PS; phosphatidylserine; TIM-4; T-cell immunoglobulin and mucin 4; MOG; myelin o
Keywords: فاکتور 8; Haemophilia A; Haemophilia B; Prophylaxis; Factor VIII; Factor IX;
Keywords: فاکتور 8; Early intervention (education); Hemophilia; Illness behavior; Pain; Quality of life; Rehabilitation; FVIII; factor VIII; FIX; factor IX; IBQ; Illness Behavior Questionnaire; RMAV; repeated-measures analysis of variance; VAS; visual analog scale;
Keywords: فاکتور 8; Hemophilia; Factor VIII; Platelets; Primary hemostasis; Bleeding time;
Keywords: فاکتور 8; thromboembolic event; hypercoagulable state; blood clot; A2AP; α2-antiplasmin; ACTH; Adrenocorticotropic hormone; ATIII; Antithrombin III; BMI; Body mass index; CRH; Corticotropin-releasing hormone; DVT; Deep-vein thrombosis; FVIII; Factor VIII; NIH; Na
Keywords: فاکتور 8; Oral contraceptives; Venous thromboembolism; D-dimer; Factor VIII; Protein C;
Keywords: فاکتور 8; Hemophilia A; Factor VIII; Inhibitors; Innate immunity; Clearance; Immune tolerance; Antigen presenting cells;
Keywords: فاکتور 8; MELD; Model for End-stage Liver Disease; vWF-Ag; von Willebrand factor antigen; PC; protein C; AT; antithrombin; FVIII; factor VIII; PH; portal hypertension; VB; variceal bleeding; AUC; area under the curve; von Willebrand factor antigen; Procoagulant imb
Keywords: فاکتور 8; aPCC; activated prothrombin complex concentrate; aPL; antiphospholipid; FIX; factor IX; FMD; flow-mediated dilatation; FV; factor V; FVIII; factor VIII; HA; hemophilia A; HB; hemophilia B; HIV; human immunodeficiency virus; IMT; intima-media thickness; MT
Keywords: فاکتور 8; APC; antigen-presenting cells; BcR; B cell receptor; EMA; European Medicines Agency; Fc; crystallizable fragment; FcγR; receptor for IgG Fc portion; FcRn; neonatal Fc receptor; FVIIa; activated factor VII; FVIII; factor VIII; GLP-1; glucagon-like peptide
Keywords: فاکتور 8; Testicular neoplasms; Chemotherapy, adjuvant; Cisplatin; Bleomycin; Cardiovascular diseases; Carotid intima media thickness; Von Willebrand factor; Factor VIII; Risk factors; Growth differentiation factor 15;
Keywords: فاکتور 8; structural bioinformatics; blood coagulation; cancer; factor VIII; factor V; neuropilin
Keywords: فاکتور 8; antenatal diagnosis; carrier; factor IX; factor VIII; haemophilia; inhibitors; recombinant
Keywords: فاکتور 8; Haemophilia; Factor VIII; Factor IX; Gene therapy; Vectors
Keywords: فاکتور 8; Whole blood; Red cell concentrates; Platelet concentrates; Plasma; Overnight hold; Factor VIII; 2,3-DPG; Recovery; Survival; Bacterial contamination
Keywords: فاکتور 8; VTE; Venous thromboembolism; CVCs; Central venous catheters; aPTT; Activated partial thromboplastin time; CT; Computed tomography; CI; Confidence interval; (F1.2); Prothrombin fragment 1.2; (TAT); Thrombin-antithrombin; FVIII: C; FVIII coagulant activity;
Keywords: فاکتور 8; CLD; chronic liver disease; CP; Child Pugh; PT-INR; prothrombin time-international normalized ratio; VTE; venous thromboembolism; RR; relative risk; ETP; endogenous thrombin potential; PC; protein C; FVIII; factor VIII; BCS; Budd-Chiari syndrome; NC-PVT;
Keywords: فاکتور 8; NAFLD; non-alcoholic fatty liver disease; NASH; non-alcoholic steatohepatitis; ETP; endogenous thrombin potential; PICI; Protac® induced coagulation inhibition; Factor VIII; Protein C; Protac®; Thrombomodulin; Thrombin generation;
Keywords: فاکتور 8; ADP; adenosine diphosphate; AE2; anion exchanger 2; Ala; alanine; AMP; adenosine monophosphate; AP; alkaline phosphatase; Arg; arginine; ATP; adenosine triphosphate; ASGP-R; asialoglycoprotein receptor; Asn; asparagine; ASOR; asialoorosomucoid; BDL; bile
Subcutaneous administration of Lyso-phosphatidylserine nanoparticles induces immunological tolerance towards Factor VIII in a Hemophilia A mouse model
Keywords: فاکتور 8; FVIII; Factor VIII; PS; phosphatidylserine; HA; Hemophilia A; Tregs; regulatory T cells; Lyso-PS; Lyso-phosphatidylserine; DMPC; dimyrisotylphosphatidylcholine; OVA; ovalbumin; GFP; green fluorescent protein; SC; subcutaneous; IV; intravenous; APC; antige
Pleiotropic effects of n-6 and n-3 fatty acid-related genetic variants on circulating hemostatic variables
Keywords: فاکتور 8; AA; African American; aPTT; activated partial thromboplastin time; ARIC; the Atherosclerosis Risk in Communities Study; CHS; the Cardiovascular Health Study; DHA; docosahexaenoic acid; DPA; docosapentaenoic acid; EA; European ancestry; EPA; eicosapentaeno
Biochemical characterization and immunogenicity of Neureight, a recombinant full-length factor VIII produced by fed-batch process in disposable bioreactors
Keywords: فاکتور 8; Hemophilia A; Factor VIII; Immunogenicity; Disposable fed-batch production technology; CHO cell line;
HIF1-alpha Regulates Acinar Cell Function and Response to Injury in Mouse Pancreas
Keywords: فاکتور 8; Mouse Model; Fibrinogen; Blood Clotting; Factor VIII; AP; acute pancreatitis; Fib-γD; fibrinogen-γ dimers; FVIII; factor VIII; HIF1α; hypoxia-inducible factor-1α; TF; tissue factor; VEGF; vascular endothelial growth factor;
Venous thromboembolism, factor VIII and chronic kidney disease
Keywords: فاکتور 8; Factor VIII; Kidney diseases; Venous thromboembolism; von Willebrand factor; ABO blood-group system;
The effect of unmeasurable endogenous plasma factor activity levels on factor VIII dosing in patients with severe hemophilia A
Keywords: فاکتور 8; Factor VIII; Hemophilia A; Individualized medicine; Patient-specific modeling; Pharmacokinetics;
Risk factors for inhibitor development in severe hemophilia A
Keywords: فاکتور 8; Factor VIII; Inhibitor; Gene variants; Polymorphism; Risk factors; FVIII products;
A Cell Culture Platform to Maintain Long-term Phenotype of Primary Human Hepatocytes and Endothelial Cells
Keywords: فاکتور 8; Micropatterned Cocultures; Tricultures; LSECs; HUVECs; 3T3-J2 Fibroblasts; CD31; cluster of differentiation 31; CD54; cluster of differentiation 54; cDNA; complementary DNA; CYP450; cytochrome P-450; ECM; extracellular matrix; F8; factor VIII; GAPDH; glyc
PAPERSAn extra X does not prevent acquired hemophilia - Pregnancy-associated acquired hemophilia A
Keywords: فاکتور 8; Acquired hemophilia A (AHA); Peripartum AHA; Factor VIII; Bleeding disorders; Postpartum hemorrhage (PPH);
Full Length ArticleChoice of factor VIII/IX regimen in adolescents and young adults with severe or moderately severe haemophilia. A French national observational study (ORTHem 15-25)
Keywords: فاکتور 8; Factor VIII; Factor IX; Prophylaxis; On-demand treatment; Age groups; Haemorrhage;
An Open-label, Single-dose, Pharmacokinetic Study of Factor VIII Activity After Administration of Moroctocog Alfa (AF-CC) in Male Chinese Patients With Hemophilia A
Keywords: فاکتور 8; age groups; China; factor VIII; pediatrics; pharmacokinetics; recombinant;
Cellular uptake of coagulation factor VIII: Elusive role of the membrane-binding spikes in the C1 domain
Keywords: فاکتور 8; Factor VIII; Low density lipoprotein receptor-related protein 1; Receptor-mediated endocytosis; α2-macroglobulin; Factor V;
Hemofilia adquirida: epidemiologÃa, clÃnica, diagnóstico y tratamiento
Keywords: فاکتور 8; Hemofilia adquirida; Factor VIII; Inhibidor del factor viii; Autoanticuerpos antifactor viii; Tratamiento antihemorrágico; Erradicación del inhibidor del factor viii; Acquired haemophilia; Factor VIII; Factor VIII Inhibitor; Anti-Factor VIII autoantibod
Hemophilia A inhibitor treatment: the promise of engineered T-cell therapy
Keywords: فاکتور 8; BCR; B-cell receptor; CAR; chimeric antigen receptor; FVIII; factor VIII; HLA; human leukocyte antigen; ITI; immune tolerance induction; ITAMs; immunoreceptor tyrosine-based activation motifs; MHC; major histocompatibility complex; MBP; myelin basic pro
Gut-derived endotoxin stimulates factor VIII secretion from endothelial cells. Implications for hypercoagulability in cirrhosis
Keywords: فاکتور 8; Endotoxin; Cirrhosis; Factor VIII; Hypercoagulability; von Willebrand factor; LPS;
A common polymorphism decreases LRP1 mRNA stability and is associated with increased plasma factor VIII levels
Keywords: فاکتور 8; (LRP1); lipoprotein receptor-related protein 1; (FVIII); factor VIII; (AIS); acute ischemic stroke; (SNPs); single-nucleotide polymorphisms; (NMD); nonsense-mediated decay; (FIXa); factor IXa; (FX); factor X; (FXa); factor Xa; (vWF); von Willebrand factor
Engineering less immunogenic and antigenic FVIII proteins
Keywords: فاکتور 8; Factor VIII; Epitopes; Anti-drug antibodies; Immunogenicity; Antigenicity;
War and peace: Factor VIII and the adaptive immune response
Keywords: فاکتور 8; Hemophilia A; Factor VIII; Inhibitors; Adaptive immune response; B cells; Plasma cells;
Coagulation parameters in patients with cirrhosis and portal vein thrombosis treated sequentially with low molecular weight heparin and vitamin K antagonists
Keywords: فاکتور 8; Anticoagulation; Anti-FXa activity; Antithrombin; Factor II; Factor VIII; INR; Protein C; Thrombin generation;
Effect of Biophysical Properties of Phosphatidylserine Particle on Immune Tolerance Induction Toward Factor VIII in a Hemophilia A Mouse Model
Keywords: فاکتور 8; protein delivery; lipids; phosphatidylserine; immunology; immune tolerance; BMDCs; bone marrow derived dendritic cells; FVIII; factor VIII; HA; hemophilia A; Nabs; anti-FVIII neutralizing antibodies; PS; phosphatidylserine;
A Model for Predicting Persistent Elevation of Factor VIII among Patients with Acute Ischemic Stroke
Keywords: فاکتور 8; Ischemic stroke; blood coagulation; biomarker; thrombosis; factor VIII;
Strategies to target long-lived plasma cells for treating hemophilia A inhibitors
Keywords: فاکتور 8; Factor VIII; Hemophilia A; Inhibitors; Plasma cells; Immune tolerance; Immunomodulation; AMD3100; G-CSF;
Recombinant factor VIII Fc (rFVIIIFc) fusion protein reduces immunogenicity and induces tolerance in hemophilia A mice
Keywords: فاکتور 8; FVIII; factor VIII; rFVIIIFc; recombinant human factor VIII Fc; BDD; B-domain deleted; FL-rFVIII; full length recombinant factor VIII; Treg; regulatory T-cells; TNF-α; tumor necrosis factor-α; IFN-γ; Interferon-γ; Hemophilia A; Immune tolerance; Regul
Część I: Wytyczne postępowania w hemofilii A i B niepowikłanej inhibitorem czynnika VIII i IX (wydanie zaktualizowane)
Keywords: فاکتور 8; hemofilia A; hemofilia B; profilaktyka; krwawienia; wytyczne; Polska; czynnik VIII; czynnik IXHaemophilia A; Haemophilia B; Prophylaxis; Bleeding; Guidelines; Poland; Factor VIII; Factor IX